Rachel Arthurs and Meerah Ghaderzadeh awarded EphMRA Young Professional Conference Grants
We’re delighted to announce that Rachel Arthurs and Meerah Ghaderzadeh have both been awarded EphMRA Young Professional Conference Grants, enabling them to attend the association’s annual conference in Antwerp later this year.
The new scheme, which EphMRA launched in February, awards five researchers with less than three years’ experience in healthcare market research the opportunity to attend the three-day event in June. Over 20 young professionals from member organisations (both industry and agency side) applied for the five grants and we are delighted that two of those were awarded to members of the Research Partnership team.
Research Partnership executive has scientific papers published in The Journal of Clinical Endocrinology & Metabolism
We’re very proud to announce that one of our Field Executives, Yoshibye Crustna contributed to two articles; ‘The effects of Peptide YY on the Hypothalamic-Pituitary-Gonadal Axis in Healthy Men’ and ‘The effects of Glucagon-like Peptide-1 on the Reproductive Axis in Healthy Men’ last month.
Both articles have been published in The Journal of Clinical Endocrinology & Metabolism which features in the Oxford Academic Journals.
Research Partnership has once again been ranked in the top 50 fastest growing privately-owned pharma companies in the UK
Research Partnership has once again been ranked in the top 50 fastest growing privately-owned pharma companies in the UK.
Pharma Times magazine has released its annual Alantra Pharma Fast 50 report. This year Research Partnership has been ranked number 29, with a compound annual growth rate of 17%. The company is also the highest ranked research consultancy.
Catching up with Coronavirus: The race to contain the outbreak is on
As Coronavirus continues to spread across the globe, Rachel Howard explores what pharma is doing to advance research into the virus, considering lessons learned from previous public health emergencies of international concern.
Over the last month, our newsfeeds have increasingly been dominated by updates on the novel coronavirus (COVID-19) outbreak. Believed to have originated in a live animal market in the Chinese city of Wuhan, at the time of publishing COVID-19 has registered over 75,000 confirmed cases and 2000 deaths, with 29 countries and territories affected. nCoV is in the same family as SARS (Severe Acute Respiratory Syndrome), another strain of coronavirus identified in 2003. While nCoV looks likely to have a lower fatality rate, it has spread much more quickly, with the number of reported cases already having rapidly overtaken SARS and continuing to grow by the day. All indications suggest the virus is highly contagious – including, critically, at the stage before an individual displays any symptoms of infection. This outbreak was declared as a public health emergency of international concern (PHEIC) by the World Health Organization (WHO) on 30th January 2020, making it the sixth such emergency since the International Health Regulations came into force in 2005: H1N1 influenza virus (swine flu) in 2009 Wild poliovirus resurgence in 2014 West Africa Ebola virus 2014 Zika virus in 2016 Kivu Ebola virus in 2019 Declaring an outbreak as a PHEIC, in…
Announcing a change of leadership at the US Philadelphia office
Research Partnership’s Philadelphia office is announcing a change of leadership from the start of 2020. President Harriet Kozak will be stepping down in order to take retirement at the end of 2019, and will be replaced by Sabera Hyderally, current Director of MedTech, North America, who will take over as the Head of the Philadelphia office from 2nd January 2020.